+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Analysis: Spiriva

  • PDF Icon

    Drug Pipelines

  • 35 Pages
  • February 2018
  • Region: Global
  • Citeline
  • ID: 4489134
Drug Overview

Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for use in chronic obstructive pulmonary disease (COPD) and is available in a dry-powder inhaler (HandiHaler) and soft mist inhaler (Respimat) device. Spiriva exhibits pharmacological effects in the airways through inhibition of M1 and M3 receptors at the smooth muscle, leading to bronchodilation. It is indicated for the long-term treatment of COPD-associated bronchospasm and for the management of exacerbations. Spiriva was the first LAMA on the market, making it the gold-standard monotherapy in COPD. It is also approved for use in asthma.

Table of Contents

1 Product Profiles
  • Spiriva: Asthma

  • Spiriva: Chronic obstructive pulmonary disease (COPD)

List of Figures
Figure 1: Symbicort for asthma - SWOT analysis
Figure 2: The author’s drug assessment summary of Spiriva in asthma
Figure 3: The author’s drug assessment summary of Symbicort in asthma
Figure 4: The author’s drug assessment summary of Spiriva for COPD

List of Tables
Table 1: Spiriva drug profile
Table 2: Spiriva pivotal trial data in asthma
Table 3: Spiriva sales for asthma across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 4: Spiriva drug profile
Table 5: Phase III trials for Spiriva HandiHaler in COPD
Table 6: Spiriva Respimat’s long-term TIOSPIR study against Spiriva HandiHaler
Table 7: Outcomes of Spiriva’s UPLIFT trial

Companies Mentioned

  • Boehringer Ingelheim